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The Journal of Immunology
Influenza Vaccination Generates Cytokine-Induced Memory-
like NK Cells: Impact of Human Cytomegalovirus Infection
Martin R. Goodier,* Ana Rodriguez-Galan,* Chiara Lusa,* Carolyn M. Nielsen,*
Alansana Darboe,*,† Ana L. Moldoveanu,* Matthew J. White,* Ron Behrens,‡ and
Eleanor M. Riley*
Human NK cells are activated by cytokines, immune complexes, and signals transduced via activating ligands on other host cells. After
vaccination, or during secondary infection, adaptive immune responses can enhance both cytokine-driven and Ab-dependent NK cell
responses. However, induction of NK cells for enhanced function after in vitro exposure to innate inflammatory cytokines has also been
reported and may synergize with adaptive signals to potentiate NK cell activity during infection or vaccination. To test this hypothesis,
we examined the effect of seasonal influenza vaccination on NK cell function and phenotype in 52 previously unvaccinated individuals.
Enhanced, IL-2–dependent, NK cell IFN-g responses to Influenza A/California/7/2009 virus were detected up to 4 wk postvaccination
and higher in human CMV (HCMV)-seronegative (HCMV2) individuals than in HCMV-seropositive (HCMV+) individuals. By
comparison, robust NK cell degranulation responses were observed both before and after vaccination, due to high titers of naturally
occurring anti-influenza Abs in human plasma, and did not differ between HCMV+ and HCMV2 subjects. In addition to these IL-2–
dependent and Ab-dependent responses, NK cell responses to innate cytokines were also enhanced after influenza vaccination; this
was associated with proliferation of CD572 NK cells and was most evident in HCMV+ subjects. Similar enhancement of cytokine
responsiveness was observed when NK cells were cocultured in vitro with Influenza A/California/7/2009 virus, and this was at least
partially dependent upon IFN-abR2. In summary, our data indicate that attenuated or live viral vaccines promote cytokine-induced
memory-like NK cells and that this process is influenced by HCMV infection. The Journal of Immunology, 2016, 197: 313–325.
L
ymphoid and myeloid cells can be primed or trained
during pathogen exposure, leading to enhanced responses
on reinfection (1, 2). The initial inflammatory cytokine
response to infection shapes the subsequent immune response,
different classes of pathogen inducing characteristic cytokine
signatures, with lasting consequences for innate as well as adap-
tive cells (1). In the case of viral infections, different combinations
and kinetics of innate cytokines, including IFN-a, IL-12, IL-15,
and IL-18, activate NK cells within the first few hours and days of
infection (3–6). These innate cytokines can also preactivate NK
cells, leading to the formation of memory-like NK cells with
enhanced capacity for cytokine production, degranulation, and
target cell lysis (7–10). In mice, responses of cytokine pre-
activated NK cells are maintained after homeostatic proliferation
and can persist for months after adoptive transfer, demonstrating
further key features of immune memory formation (7, 11). These
memory-like NK cells contrast with those that have received on-
going short duration stimulation with cytokines such as IL-15 (12–
14). Human NK cells preactivated in vitro by cocktails of IL-12,
IL-15, and IL-18 and rested for up to 21 d subsequently produce
more IFN-g after restimulation, and this phenotype is maintained
after proliferative expansion (8). Whether cytokine-induced NK
cell preactivation occurs in vivo during human infection or vac-
cination and, if so, how long this preactivated state persists and
whether it potentiates the adaptive response is unknown. For
example, influenza infection generates a characteristic systemic
cytokine signature comprising IFN-a, IL-15, and IL-10 (3, 15–
17), but it is not known whether this is sufficient to preactivate NK
cells in vivo. Modest enhancement of IFN-g (and IL-22) responses
of mixed PBMC to heterologous bacterial pathogens has been
reported up to 3 months after bacillus Calmette-Gue´rin vaccination
and has been postulated as the mechanism underlying the long-
term, nonspecific effects of bacillus Calmette-Gue´rin vaccines, but
the sources of these cytokines are unknown (18, 19).
The molecular basis for generation of cytokine-induced memory-
like NK is also, as yet, incompletely understood. Upregulation of
CD25 (IL-2Ra) is characteristic of memory-like NK cells in hu-
mans (20) and in mice (21) and has also been reported shortly after
influenza vaccination (22). CD25 upregulation on NK cells after
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vaccination and consequent enhanced sensitivity to IL-2 is associ-
ated with markedly increased, T cell/IL-2–dependent, NK cell IFN-g
and degranulation responses to vaccine Ags but would not easily
explain enhanced responsiveness to other cytokines (23–26). Ad-
ditionally, preactivation of NK cells with a mixture of IL-15 plus
IL-12 plus IL-18 leads to epigenetic modifications including com-
plete demethylation of the conserved upstream noncoding se-
quences of the IFN-g gene (27). Interestingly, similar modifications
are reported in the expanded NKG2Chi NK cell subset in human
CMV (HCMV)–infected subjects (27), suggesting that signaling
through NKG2C (mediated, for example by HLA-E/CMV peptide
complexes), with or without additional cytokine stimuli, also results
in sustained functional modification of NK cells. The functional
characteristics and longevity of cytokine-induced memory-like NK
cells may therefore depend on an individual’s HCMV infection
status. Moreover, the precise mixture of activating cytokines is
important with IL-15 plus IL-12, IL-15 plus IL-18, or IL-15 alone
leading to only partial demethylation of the IFNG locus (27).
In order to begin to understand the in vivo relevance of cytokine-
induced memory-like NK cells in humans, we have characterized
human NK cells before and after vaccination with either killed or live
attenuated influenza viruses. We observe upregulation of NK cell
responses to influenza virus after vaccination, with kinetics directly
reflected in the ability of these cells to respond to innate cytokines.
Moreover, the threshold for vaccine-induced effects is much higher
in HCMV-seropositive (HCMV+) individuals, resulting in reduced
responsiveness to vaccines. We also demonstrate, for the first time
to our knowledge, that influenza virus can preactivate human NK
cells in vitro, and this effect is at least partially dependent upon
IFN-abR2 mediated signals.
Materials and Methods
Subject recruitment and sample collection
Fifty-two healthy adult volunteers (median age 37.5 y; range 21–63 y) were
enrolled into the study after providing informed consent. The study was
approved by the ethical committee of the London School of Hygiene and
Tropical Medicine (reference number 6237). None of the subjects had been
previously vaccinated against influenza, and none had experienced influenza-
like symptoms during the previous 6 mo. Subjects were randomly assigned
to receive a single dose of 2012–2013 seasonal trivalent influenza vaccine
(TIV) by the intradermal (ID; Intanza; Sanofi Pasteur MSD), i.m. (Split
Virion BP; Sanofi Pasteur MSD), or intranasal (IN; Fluenz; AstraZeneca)
routes. Randomization was structured so that the three arms of the study
could be matched according to age and gender. The i.m. and ID vaccines
contain chemically inactivated virus, whereas the IN vaccine contains live
attenuated virus. The vaccines were all preservative free and not adjuvanted.
Heparinized blood was collected prior to (baseline sample) and 2, 4, and
12 wk after vaccination. Plasma samples were stored for assay of Abs to
influenza and HCMV and for use in autologous cell cultures. PBMC were
separated by standard Histopaque (Sigma-Aldrich) gradient centrifugation
and processed within 4 h of blood collection for immediate (ex vivo) flow
cytometry. Remaining cells were cryopreserved at 1 3 107 cells/ml in
RPMI 1640, 40% FCS, and 10% DMSO (Sigma-Aldrich), within 4 h of
blood collection. Cells were stored for 18 h at 280˚C in Nalgene cryo-
boxes with isopropanol coolant prior to transfer to liquid nitrogen for
longer-term storage (25, 28).
Cell culture conditions, NK cell activation, and IFN-a
measurement
For each individual vaccinee, cells collected at baseline and at each post-
vaccination time point were tested side-by-side. Cryopreserved PBMC were
thawed, washed, and counted on Fastread counting slides (Immune Systems),
as previously described withmedian yield of 56% and viability by trypan blue
exclusion of 98% (25, 26, 28). Cells were rested for 4–6 h, in the absence of
exogenous cytokines, prior to stimulation. Briefly, 2 3 105 PBMC were
cultured for a total of 6 h (for T cell assays) or 18 h (to enable detection of
T cell–dependent NK cell responses) in culture medium alone or with
inactivated TIV (Split Virion BP; Sanofi Pasteur MSD) or inactivated
Influenza A/California/7/2009 (H1N1) influenza virus (vNYMC-X179A;
National Institute for Biological Standards and Control, Potters Bar, U.K.)
in the presence or absence of low concentrations of cytokines (LCC), IL-12
(PeproTech, London, U.K.; 12.5 pg/ml) plus IL-18 (R&D Systems, Ox-
ford, U.K.; 10 ng/ml). Cells incubated in culture medium alone or in LCC
only were used as internal negative controls. Cells were also stimulated
with MHC class I–deficient K562 cells (PBMC: K562 ratio of 2:1) or high
concentrations of cytokines (HCC), IL-12 (5 ng/ml) plus IL-18 (50 ng/ml).
GolgiStop (containing Monensin; 1/1500 concentration; BD Biosciences,
Oxford, U.K.) and GolgiPlug (containing Brefeldin A; 1/1000 final con-
centration; BD Biosciences) were added after 3 h for T cell assays and
after 15 h for NK cell assays. All assays were performed in 10% pooled
AB serum, batch tested for performance in NK cell assays (Sigma-Aldrich)
unless otherwise stated. In vitro neutralization experiments were per-
formed using a rat anti-human IL-2 Ab (rat IgG2a; clone MQ1-17H12,NA/
LE; BD Biosciences) or a rat IgG2a control reagent (eBioscience). To
determine the role of influenza-specific IgG on NK cell responses, pooled AB
plasma was depleted of IgG using a protein G Sepharose column (Millipore),
as previously described (25). IFN-a was measured in tissue culture super-
natants using a commercially available ELISA kit (PBL Assay Science).
In vitro preactivation of NK cells with influenza virus
Preactivation of NK cells in vitro was performed essentially as previously
described (8). PBMC (2 3 106/ml) were cultured in 1 ng/ml IL-15 alone
(control) or in IL-15 combined with either inactivated influenza H1N1
virus or HCC (IL-12 5 ng/m plus IL-18 50 ng/ml). After 16 h, cells were
washed three times and maintained for a further 14 d in medium containing
1 ng/ml IL-15, replacing the IL-15–enriched medium every 2 to 3 d.
Preactivated cells and control cells were restimulated for 6 or 18 h with
different concentrations of IL-12 combined with either IL-18 or IL-15. To
test for cytokine dependence of the preactivation process, neutralizing Abs
to IL-2 (see Cell culture conditions, NK cell activation, and IFN-a mea-
surement), IL-12 (clone NA/LE, C8.6, mouse IgG1 [mIgG1]; BD Biosci-
ences), or IL-18 (clone 125-2H, mIgG1; R&D Systems) or blocking Ab
against IFN-abR2 (clone MMHAR2, mIgG2a; Merck Millipore) were
added to H1N1-stimulated cultures. Isotype-matched control reagents were
used as controls (BD Biosciences).
Estimation of plasma anti-influenza IgG and anti-HCMV IgG
concentrations
Levels of total IgG against TIV (Split Virion BP; Sanofi Pasteur MSD) or
inactivated H1N1 were determined by ELISA as previously described (25,
29). Briefly, plasma samples were applied to Ag-coated ELISA plates
(Nunc Maxisorp; Nunc) and bound IgG detected with goat anti-human
IgG-peroxidase (Sigma-Aldrich) as the secondary Ab and SIGMAFAST
OPD (Sigma-Aldrich) as the substrate. Ab levels were calculated as ar-
bitrary ELISA units (AEU) with reference to values obtained for an in-
house, high-titer standard plasma (assigned a value of 1000 AEU). The
commercial AB serum used for tissue culture was estimated to contain
413.4 AEU against TIV and 273.7 AEU against H1N1, reflecting wide-
spread natural exposure to influenza among the blood donor community.
IgG-depleted AB plasma contained 7.6 and 14.6 AEU against TIV and
H1N1, respectively. HCMV infection status was determined using a
commercially available ELISA kit for anti-HCMV pp65 IgG (Biokit).
Nineteen of the 52 study subjects (37%) were HCMV IgG seropositive.
Abs and flow cytometric analysis
Phenotypic and functional analysis of ex vivo– and in vitro–stimulated NK
cells was performed with the following mAbs: anti–CD3-V500 (clone
UCHT1), anti–CD56-PECy7 (B159), anti–CD107a-FITC (H4A3) (all from
BD Biosciences); anti–CD57-e450 (TB01), anti–CD16-allophycocyanin
(CB16), anti–CD25-PerCP Cy5.5 (BC96) (all from eBioscience); or anti-
CD71 FITC (OKT9; eBioscience), and anti-NKG2C PE (134591; R&D
Systems). For in vitro assays, anti-CD107a Ab was added at the beginning of
the culture. After staining for cell-surface markers, cells were fixed, per-
meabilized (Cytofix-Cytoperm; BD Biosciences), and washed (Perm-wash
buffer; BD Biosciences) and either analyzed directly or stained with anti–
IFN-g–APC-eFluor 780–conjugated Ab (4S.B3; eBioscience). Ki67 staining
(PerCP-eFluor 710–conjugated Ab; clone 20Raj1) was performed after in-
clusion of an APC-eFluor 780–conjugated fixable live-dead discriminatory
dye with surface markers and subsequent fixation with Foxp3 intranuclear
staining kit (all from eBioscience). Using the same protocols used for in-
tracellular NK cell cytokine staining, T cells were labeled using anti–CD3-
V500, CD56-PECy7, IL-2–allophycocyanin (MQ1 17-H12), IFN-g–PE
(B27) (all from BD Biosciences), CD4e450 (OKT4), and CD8-PECy5 (RPA-
T8) (both from eBioscience). For ex vivo analysis, cells were additionally
labeled with the following mAbs: anti–CD3-V500, anti–CD56-PECy7, and
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anti–CD94-FITC (HP-3D9) (BD Biosciences); anti–NKG2C-PE and anti–
NKG2A-allophycocyanin (Z199; Beckman Coulter); and anti–CD8-PECy5,
anti–CD57-e450, and anti–CD16-APC–eFluor 780 (eBioscience). Cells were
acquired on an LSRII flow cytometer (BD Biosciences) using FACSDiva
software. Data analysis was performed using FlowJo V10 (Tree Star).
FACS gates set on unstimulated cells (medium alone or isotype controls)
were applied across all samples and all conditions. Responses in which
the gated subset contained ,100 events were excluded. CD572 subsets
were gated using an isotype-matched control reagent (mIgG1–eFluor 450;
eBioscience) and CD57+ subsets were gated according to a standardized
mean fluorescence intensity (MFI) of 3000, with CD57int cells lying between
these populations. Sample gating strategies are shown in Figs. 1 and 8.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 6.02
(GraphPad). Linear trends were evaluated using repeated-measures
ANOVA. Functional responses between vaccination time points were
compared using Wilcoxon signed-rank test, and intergroup comparisons
between HCMV+ and HCMV-seronegative (HCMV2) individuals were
performed using Mann–Whitney U test. Significance levels are assigned as
*p , 0.05, **p , 0.01, ***p , 0.001, and ****p , 0.0001 for all tests.
Results
Potentiation of NK cell responses after influenza vaccination
To examine the effect of influenza vaccination on NK cell responses,
we compared NK cell phenotype and function (by flow cytometry)
among 52 healthy, previously unvaccinated, adult volunteers
before (0; baseline) and 2, 4 and 12 wk after a single dose of
seasonal TIV. Volunteers were randomly assigned to receive i.m.
(n = 17), ID (n = 17), or IN (n = 18) vaccine. NK cell functional
responses were assayed 18 h after in vitro restimulation to dissect
both T cell–dependent and –independent responses. The route of
vaccination had no significant effect on cellular immune responses,
with enhancement of NK cell IFN-g production and robust CD107a
and CD25 expression being observed upon in vitro stimulation with
influenza virus after vaccination via all three routes (data not
shown). Data from all three arms of the study were therefore pooled
for the majority of the analyses.
In vitro stimulation of PBMC with inactivated (vaccine strain)
H1N1 virus induced significant upregulation of IFN-g, CD25, and
CD107a expression in baseline samples (H1N1 versus no Ag at
week 0) (Figs. 1, 2A–C), and these responses were augmented in the
presence of very low concentrations of IL-12 plus IL-18 (Figs. 1,
2D–F), suggesting limited induction of these cytokines by inacti-
vated influenza virus in vitro. Moreover, IFN-g responses to H1N1
were significantly enhanced 2 and 4 wk postvaccination in many, but
not all, individuals: frequencies of IFN-g+ cells were higher 2 wk
postvaccination than before vaccination in 28 out of 52 subjects and
higher 4 wk after vaccination than before vaccination in 20 out of 52
FIGURE 1. NK cell responses to influenza H1N1 virus. Flow cytometry plots are shown for NK cell IFN-g (A), CD107a (B), and CD25 (C) responses to
inactivated influenza virus in a representative individual 2 wk after vaccination. Responses were compared in gated NK cells cultured in, from left to right,
medium alone, H1N1 Ag only, LCC (IL-12 12.5 pg/ml plus IL-18 10 ng/ml) alone, LCC plus H1N1, and HCC alone (IL-12 5 ng/ml plus IL-18 50 ng/ml).
Percentages of total NK cells responding to the different stimuli are shown on each plot.
The Journal of Immunology 315
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subjects. However, this effect had waned by 12 wk postvaccination
(Figs. 1A, 2A). Postvaccination responses were further enhanced by
very low concentrations of exogenous IL-12 plus IL-18 (LCC) such
that enhancement of responses by vaccination was evident in 30 out
of 52 individuals after 2 wk and 25 out of 52 individuals after 4 wk
(Figs. 1A, 2D). NK cell CD107a responses against influenza H1N1
(Fig. 2B) and TIV (Supplemental Fig. 1) were high in baseline
samples, reflecting high levels of anti-influenza Abs in the pooled
human plasma used for culture (see Materials and Methods). There
was a very modest effect of vaccination on CD107a responses at
2 wk postvaccination and no effect of vaccination on CD25 expres-
sion (Figs. 1B, 1C, 2B, 2C, 2E, 2F). Similar responses were
observed after restimulation with whole TIV, albeit at lower fre-
quency (Supplemental Fig. 1).
The modest (but statistically significant) increase in production of
IFN-g in response to low-dose IL-12 plus IL-18 observed 2 wk after
influenza vaccination (Fig. 2D, inset graph) is highly reminiscent of
the generation of memory-like NK cells in vitro with cytokine
cocktails (8). To investigate this further, we tested whether influenza
vaccination enhanced the response to higher concentrations of cy-
tokines (in this case, 5 ng/ml IL-12 and 50 ng/ml IL-18) that were
more in line with those used previously to cytokine-mediated human
NK cell preactivation (Figs. 1, 2G–I) (8). Across the entire vacci-
nation cohort, the proportions of NK cells producing IFN-g and
degranulating (i.e., expressing CD107a at the cell surface) in re-
sponse to high concentrations of IL-12 plus IL-18 were significantly
higher after vaccination, with increased frequencies compared with
baseline values both 2 wk (29 out of 52 individuals) and 4 wk (32
out of 52 individuals) after influenza vaccination. Again, this effect
had waned by 12 wk postvaccination (Fig. 2G, 2H). There was no
effect of recent vaccination on the frequency of NK cells expressing
after CD25 in vitro stimulation (Fig. 2I). Interestingly, in vitro
restimulation with K562 cells also resulted in a small but signifi-
cant increase in the frequencies of NK cells producing IFN-g 4 wk
postvaccination compared with baseline (Supplemental Fig. 2).
Influenza virus–stimulated IFN-g production postvaccination
is dependent on IL-2, whereas CD107a expression requires
IL-2 and immune complexes
We next investigated whether, in addition to the intrinsic effects of
vaccination on NK cell cytokine responsiveness, enhancement of
NK cell IFN-g and CD107a responses to H1N1 virus postvaccina-
tion also depended on Ag-specific T cells and plasma IgG. Assays
were carried out with whole (inactivated) H1N1 virus using mixed
PBMC (containing detectable influenza-specific IL-2+CD4+ T cells;
Supplemental Fig. 3) and pooled human AB serum containing anti-
H1N1 Abs to standardize the level of influenza-specific IgG in
cultures (see Materials and Methods) (Fig. 3). IL-2 blockade with a
neutralizing anti–IL-2 mAb significantly reduced NK cell IFN-g
(Fig. 3A) and CD107a (Fig. 3B) responses both at baseline and 2 wk
postvaccination compared with the isotype-matched control. IL-2
neutralization had no significant effect on CD25 upregulation
FIGURE 2. NK cell responses to influenza viruses are enhanced after influenza vaccination. PBMC were collected from 52 study subjects prior to (week
0) or after vaccination (weeks 2, 4, and 12) and cultured in vitro in culture medium alone, with vaccine strain influenza H1N1 (A–C) or with LCC (IL-12
12.5 pg/ml plus IL-18 10 ng/ml) alone or combined with H1N1 (D–F). Responses to HCC (IL-12 5 ng/ml + IL-18 50 ng/ml) were also determined before
and after vaccination (G–I). Expression of IFN-g (A, D, and G), CD107a (B, E, and H), and CD25 (C, F, and I) were analyzed within the total NK cell
population. Paired statistical comparisons of NK cell responses before and after vaccination and between virus or cytokine responses and untreated cultures
(medium) were performed using Wilcoxon signed-rank test. *p , 0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001.
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(Fig. 3C). To determine whether anti-influenza Abs also played a role
in NK activation, PBMCs were cultured in either intact AB serum (i.e.,
containing influenza-specific IgG) or in AB serum from which IgG
had been depleted. IgG depletion had no effect on IFN-g responses
(Fig. 3A) but significantly reduced both CD107a (Fig. 3B) and CD25
(Fig. 3C) responses in both baseline and 2-wk postvaccination samples.
Overall, these data indicate an important role for IL-2 in H1N1-
induced NK cell IFN-g responses both in prevaccination responses
and in the enhanced response resulting from vaccination.
In contrast, optimal CD107a responses were dependent on both
IL-2 and Ab/immune complexes, consistent with IL-2–mediated
postvaccination enhancement of CD107a responses to H1N1 in
PBMC assays in which anti-influenza IgG levels (in AB serum)
are held constant (Fig. 1B).
Vaccination does not augment Ab-dependent NK cell responses
In view of the role of serum Ab in the induction of NK cell CD107a
and CD25 responses to influenza virus, we assessed the impact of
increasing autologous plasma Ab concentrations after vaccination
on the induction of NK cell responses. Plasma IgG levels to TIVand
H1N1 were assessed at baseline, 2, 4, and 12 wk postvaccination
and compared by route of vaccination and HCMV infection status
(Fig. 4). All of the donors recruited to this study were seropositive
for IgG to TIV at baseline, and 46 out of 52 were seropositive for
H1N1, indicating widespread prior exposure to seasonal influenza.
Intramuscular or ID vaccination with inactivated TIV boosted pre-
existing concentrations of IgG to both TIV and H1N1, in both
HCMV+ and HCMV2 individuals, but there was only a very modest
systemic IgG response to the live, attenuated IN vaccine (Fig. 4A–F),
in line with previously published data on IN vaccination (30).
To determine whether boosting of anti-influenza Ab titers by
vaccination also boosted NK cell responses, baseline or postvac-
cination PBMC were cultured with TIVor H1N1 virus in medium
containing autologous plasma taken either at baseline or 4 wk after
vaccination. No effect was observed of postvaccination plasma on
IFN-g (Fig. 4G) or CD25 (Fig. 4I) responses. Surprisingly,
CD107a responses were significantly reduced when cells were
cultured in postvaccination plasma (Fig. 4H).
These data indicate that pre-existing concentrations of anti-
influenza Abs are sufficient to support NK cell degranulation
and CD25 induction in response to influenza virus in individuals
with prior exposure to seasonal influenza virus strains.
In vitro preactivation mimics the effects of vaccination
In view of the enhanced NK cell response to IL-12 plus IL-18
after vaccination (Fig. 2), we investigated whether influenza virus
H1N1 could preactivate NK cells in vitro and, if so, whether this
was cytokine mediated. Using an established protocol (8), PBMC
were incubated with inactivated influenza H1N1 virus or, as a
positive control, HCC (IL-12 5 ng/ml plus IL-18 50 ng/ml) for
16 h in the presence of a low concentration of IL-15 (1 ng/ml); IL-
15 alone provided a negative control (Fig. 5A). The cells were
washed (to remove the stimuli), maintained in IL-15 for 2 wk, and
then restimulated with varying concentrations of either IL-12 plus
IL-18 or IL-12 plus IL-15 for 6 h (Fig. 5A). Both IFN-g and
CD107a responses were higher in NK cells that had been pre-
activated in vitro with H1N1 than in NK cells maintained in IL-15
alone, and these responses were broadly similar to those induced
by preactivation with high concentrations of IL-12 and IL-18
(Fig. 5B–D). Preactivation with H1N1 or HCC had a modest but
statistically significant effect on CD25 expression in response to
IL-12 plus IL-18, but this was only evident after 18 h of cytokine
restimulation (Fig. 5E) rather than 6 h (data not shown). Of in-
terest, the proportion of CD57+ NK cells was lower in preactivated
cultures than in cultures maintained in IL-15 alone (Fig. 5F), and
there was a modest but statistically significant increase in the
proportion of NKG2A+ (but not NKG2C+) cells (Fig. 5G, 5H).
Type 1 IFNs contribute to NK cell preactivation in vitro
To determine whether, and if so which, cytokines were involved in
NK cell preactivation by H1N1 virus, the 16-h preactivation ex-
periments were repeated in the presence or absence of neutralizing
mAbs to IL-2, IL-12, or IL-18 or a blocking Ab to IFN-abR2, and
NK cells were immediately tested for IFN-g, CD107a, and CD25
expression (Fig. 6); isotype-matched Abs with irrelevant specificity
were used as negative controls. All four neutralizing or blocking
Abs significantly reduced IFN-g production by H1N1-activated NK
cells (Fig. 6A). Similar but more limited effects were observed for
CD107a expression (Fig. 6B) but only anti–IFN-abR2 significantly
FIGURE 3. IL-2 and Ab dependence of postvaccination NK cell re-
sponses to influenza. PBMC, collected at baseline (0) or 2 wk after vac-
cination, were cultured in medium alone or with H1N1 influenza virus in
the presence of anti-human IL-2 (or rat IgG2a isotype control) in either
complete or IgG-depleted (IgG2) AB serum. IFN-g (A), CD107a (B), and
CD25 (C) responses were measured among total NK cells. Data are shown
for 32 individuals (17 HCMV2 and 15 HCMV+) for whom sufficient cells
were available at both time points. Boxes represent medians and inter-
quartile ranges, whiskers represent 90th percentiles, and outliers are shown
by solid dots. Paired comparisons between treatments were performed
using Wilcoxon signed-rank test. *p , 0.05, **p , 0.01, ***p , 0.001.
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reduced CD25 expression (Fig. 6C).This experiment was then re-
peated, with neutralizing Abs present at the time of preactivation,
on cells that had then been rested in IL-15 for 14 d and restimu-
lated. In this case, however, blockade of IFN-abR2 significantly
reduced both the IFN-g (Fig. 6D) and the CD107a (Fig. 6E) re-
sponse to IL-12 plus IL-18, but neutralization of the other cytokines
had no significant effect.
To explore the hypothesis that type 1 IFNs induced in the PBMC
cultures by H1N1 virus were required for NK cell preactivation, we
assessed IFN-a and IFN-b secretion in culture supernatants of
H1N1-stimulated PBMC collected from study subjects at baseline
(before vaccination) and 2 wk after vaccination. IFN-a (at con-
centrations in excess of 100 pg/ml) was detected in cell super-
natants from the majority of study subjects at both time points
(Fig. 6F), but IFN-b was not detected (data not shown). Moreover,
a possible role for IFN-a in the upregulation of CD25 on NK cells
is supported by a direct correlation between the frequency of
CD25+ cells and the level of IFN-a in supernatants (Fig. 6G).
HCMVexposure influences NK cell responses after vaccination
Our previous cross-sectional studies have suggested that NK cells
from HCMV-uninfected individuals make superior IFN-g and
CD25 responses to vaccine Ags in vitro, in part relating to higher
frequencies of less well-differentiated CD572 NK cell subsets (26,
31). As HCMV infection promotes expansion of CD57+ NK cell
subsets at the expense of CD572 subsets (28, 32–34), we reasoned
that vaccine-induced generation of memory-like NK cells could
differ between HCMV-infected (HCMV+) and HCMV-uninfected
(HCMV2) subjects.
There were marked and highly significant differences between
HCMV2 and HCMV+ subjects in their NK cell responses to in-
fluenza vaccination (Fig. 7). NK cell IFN-g responses to H1N1 and
to H1N1 plus LCC were robustly enhanced among HCMV2 indi-
viduals, but there was limited or no augmentation of the IFN-g
response among HCMV+ subjects (Fig. 7A, 7D). Although CD107a
responses did not differ between HCMV+ and HCMV2 subjects
(Fig. 7B, 7E), upregulation of CD25 was significantly greater among
HCMV2 than HCMV+ subjects both at baseline and after vacci-
nation (Fig. 7C, 7F). Moreover, CD25 upregulation by H1N1
stimulation, as measured by MFI, was significantly higher among
HCMV2 individuals than among HCMV+ individuals across the
entire vaccination time course (baseline: HCMV2, median MFI 529,
interquartile range [IQR] 477–627; HCMV+, median MFI 451, IQR
404–572, p = 0.01; week 2: HCMV2, median 550, IQR 496–636;
FIGURE 4. Boosting of anti-influenza IgG by vaccination does not enhance NK cell responses. Increased levels of serum IgG against TIV (A–C) or
H1N1 (D–F) were detected after vaccination with ID (A and D) and i.m. (B and E) but not after IN (C and F) vaccination. Data are shown as median values
with IQRs. Expression of IFN-g (G), CD107a (H), and CD25 (I) was measured in NK cells from all 52 study donors at baseline (0) or 4 wk postvaccination
(4) after culture with inactivated H1N1 virus in the presence of autologous plasma taken either at baseline (0) or 4 wk after vaccination (4). Trend analysis
was performed using one-way ANOVA with correction for multiple comparisons. Paired comparisons were made using Wilcoxon signed-rank test. *p ,
0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001.
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HCMV+, median 489, IQR 426–552, p = 0.008), and similar effects
were observed after stimulation with H1N1 plus LCC (data not
shown). In vitro stimulation with TIValso resulted in stronger IFN-g
and CD25 responses in HCMV2 individuals than in HCMV+ indi-
viduals (Supplemental Fig. 2).
However, somewhat unexpectedly, when we stratified the data by
HCMV infection status, postvaccination enhancement of NK cell
IFN-g responses to high concentrations of IL-12 plus IL-18 was
observed only among HCMV+ individuals, in whom the frequen-
cies of responding cells approached those consistently observed in
HCMV2 individuals (Fig. 7G). Stratification by HCMV serostatus
also revealed significant increases postvaccination in CD107a and
CD25 expression (Fig. 7H, 7I). Enhancement of CD107a, CD25
expression, and IFN-g production among HCMV+ subjects was
evident at 2 and 4 wk postvaccination but had waned by 12 wk
(Fig. 7G–I). Differences in the proportions of CD25+ NK cells were
mirrored in the MFI of CD25 expression, with significantly in-
creased MFI for CD25 in HCC-stimulated NK cells from HCMV+
individuals 2 wk postvaccination (baseline: median 849, IQR 745–
1061; week 2: median 1014, IQR 841–1147, p = 0.003).
NK cell differentiation status affects vaccine-induced responses
Cross-sectional studies in adults of NK cell responses to childhood
vaccine Ags have revealed that IFN-g responses are more or less
FIGURE 5. Influenza virus induces memory-like NK cells in vitro. (A) An in vitro model for memory-like NK cell generation was used to test whether
influenza H1N1 or HCC can preactivate NK cells for enhanced responsiveness after 2 wk of culture. PBMC were initially cultured for 16 h in medium alone,
with inactivated influenza H1N1 or with HCC. All cultures contained 1 ng/ml IL-15 to ensure NK cell survival. Cultures were then washed extensively and
maintained in medium (containing 1 ng/ml IL-15) for 14 d. After further washes, cells were restimulated in vitro with varying concentrations of IL-12 combined
with either IL-15 or IL-18. NK cell responses were monitored after 6 or 18 h. (B) Representative flow cytometry plots for IFN-g production after HCC (IL-12
5 ng/ml plus IL-18 50 ng/ml) restimulation of control NK cells (medium alone, no preactivation) or NK cells preactivated with H1N1 or HCC. Enhancement of
IFN-g production (C), CD107a expression (D), and CD25 expression (E) in eight individuals after NK cell preactivation with H1N1 (light gray bars) and HCC
(dark gray bars) compared with no preactivation (open bars). Cells were restimulated with the indicated concentrations of IL-12 combined with either IL-15 or
IL-18. Frequencies of NK cells expressing CD57 (F), NKG2A (G), and NKG2C (H) were determined in preactivated NK cells cultured in medium alone or
restimulated with IL-12 plus IL-18. Comparisons between culture conditions were made using Wilcoxon signed-rank test. *p , 0.05, **p , 0.01.
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restricted to the CD56bright and CD56dimCD572 NK cell subsets
but that degranulation responses are retained or enhanced among
CD57+ NK cells (25, 26). As HCMV infection leads to expansion
of the CD57+ NK cell subset, reduced postvaccination IFN-g re-
sponses among HCMV+ subjects may be due simply to differences
in subset distribution. NK cell responses to H1N1 virus were
therefore analyzed according to their expression of CD57 (Fig. 8).
Stratification of NK cell responses to H1N1 influenza by CD57
expression (see Fig. 8A for gating strategy) in HCMV+ and
HCMV2 individuals revealed that IFN-g responses were lower
within each subset in HCMV+ individuals than in HCMV2 indi-
viduals. Data for the 2-wk postvaccination time point are shown in
Fig. 8B, with similar effects evident at all other time points (data
not shown). This is consistent with previous data suggesting that
the effects of HCMV infection go beyond a simple redistribution
of NK cell subsets (25). The frequencies of NK cells expressing
CD107a upon stimulation with H1N1 virus increased significantly
with increasing CD57 expression 2 wk after vaccination but did
not differ between HCMV+ and HCMV2 individuals (Fig. 8C).
Importantly, CD25 induction by H1N1 in HCMV2 subjects did
not differ significantly by subset, whereas among HCMV+ sub-
jects CD25 induction declined with increasing CD57 expression
and was significantly lower among HCMV+ than HCMV2 donors
in the CD57+ subset (Fig. 8D).
As CD56bright and CD56dimCD572 NK subsets are enriched for
cells expressing cytokine receptors, we next analyzed whether
enhancement of IL-12 plus IL-18 responsiveness in HCMV+ in-
dividuals was due to preferential effects on these subsets (Fig.
8E–G). As expected, CD56bright and CD56dimCD572 NK subsets
from both HCMV2 and HCMV+ individuals contained higher fre-
quencies of IFN-g and CD25-expressing cells compared with the
CD57+ subset in response to IL-12 plus IL-18 (Fig. 8E, 8G).
However, in HCMV+ individuals, enhancement of these responses
after vaccination was observed across NK cell subsets, and
CD107a expression was significantly enhanced within all CD56dim
CD57-defined populations (Fig. 8F). Little or no effect was ob-
served on NK cell subset responses of HCMV2 individuals to
HCC (data not shown). These data indicate that HCC can over-
come a high activation threshold for NK cell CD25 and IFN-g
expression in vaccine-preactivated NK cells from HCMV+ indi-
viduals.
NK cell phenotype is modified by influenza vaccination
according to HCMV exposure
Although influenza vaccination influenced cytokine-driven re-
sponses across all CD57-defined NK cell subsets in HCMV+ in-
dividuals, this did not rule out the possibility that vaccination
could induce global changes in the frequencies of functional NK
cell subpopulations, as seen in the in vitro experiments described
above (Fig. 5). To determine whether the effects of influenza
vaccination on NK cell responses were attributable to gross
changes in NK cell phenotype in vivo, samples from HCMV+ and
FIGURE 6. IFN-abR2 blockade abrogates in vitro preactivation of NK cells by influenza virus (A–E). PBMCs from eight individuals were preactivated
with H1N1 in the presence of neutralizing anti–IL-2, anti–IL-12, anti–IL-18, or blocking anti–IFN-abR2 Ab or rat or mouse isotype control reagents, as
indicated. The frequencies of NK cells expressing IFN-g (A and D), CD107a (B and E), or CD25 (C) after 6-h restimulation with HCC (IL-12 5 ng/ml plus
IL-18 50 ng/ml) were measured directly (A–C) or after maintenance in IL-15 replete medium for 14 d (D and E). (F) IFN-a concentrations in culture
supernatants of H1N1-stimulated PBMCs from 32 individuals (17 HCMV2, 15 HCMV+) before (0) and 2 wk after vaccination. (G) Correlation between
H1N1-induced IFN-a concentration and H1N1-induced CD25 expression 2 wk postvaccination. Statistical comparisons between NK cells with and without
preactivation or between different neutralizing/blocking conditions were made by Mann–Whitney U test. *p , 0.05, **p , 0.01.
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HCMV2 individuals were analyzed directly ex vivo (i.e., without
in vitro restimulation) (Fig. 9). There was no evidence of any
change in the ex vivo distribution of CD56/CD57/NKG2C or
CD56/CD57/NKG2A-defined NK cell subsets after vaccination
(Fig. 9A–C), and, in contrast to previous studies (35), we did not
see any change in NKp46 expression (data not shown). Among
HCMV2 subjects, the proportion of NK cells expressing CD25
(IL-2Ra) ex vivo was significantly higher 2 wk after vaccination
than at baseline, whereas this effect was not seen in NK cells from
HCMV+ subjects (Fig. 9D), and no significant increase in ex vivo
expression of IFN-g or CD107a was detected at this or subsequent
time points (data not shown). These data are consistent with
studies previously reporting CD25 being a marker of NK cell
activation at early time points after influenza vaccination (22).
As expected, the proportion of CD57+ NK cells was higher at
baseline among HCMV+ subjects than HCMV2 subjects, and the
proportion of CD572 NK cells was lower (Fig. 9E) (25, 32, 33).
However, among HCMV+ individuals, the proportions of CD572
NK cells increased noticeably after vaccination (Fig. 9E), result-
ing in a significant increase in the ratio of CD572 to CD57+ NK
cells, which was not seen in HCMV2 subjects (Fig. 9F). Ex-
pression of Ki67, and coexpression of Ki67 with CD71 (the
transferrin receptor), on a significant proportion of both CD56bright
and CD56dimCD572 NK cells 2 wk after vaccination (Fig. 9G,
9H) is indicative of proliferation (recent cell division) within the
CD572 NK cell subset. These data are consistent with vaccination
promoting proliferation of less differentiated, cytokine-responsive
NK cells and normalization of frequencies of these cells between
HCMV2 and HCMV+ individuals, leading to improved respon-
siveness to exogenous cytokines.
Discussion
Training of lymphoid and myeloid cells upon pathogen exposure
enables them to mount superior responses upon subsequent ex-
posure (1, 2). In this study, we demonstrate that the generation of
memory-like NK cells, observed with recombinant cytokines
in vitro (8, 20), also occurs in vivo after vaccination with either
live attenuated or killed influenza virus. NK cells induced by in-
fluenza vaccination share all the characteristics of cytokine
preactivated memory-like (7) NK cells, including long-term
enhancement (for at least a month) of IFN-g responses to innate
cytokines and MHC class I–deficient target cells and a role for
CD25 upregulation and IL-2 in enhancing these responses (8, 11,
20). Taken together, our data support a model for generation of
memory-like NK cells by influenza virus involving upregulation
of CD25 by virus-induced IFN-a; selective, IL-2–driven expan-
sion of less differentiated (CD572) NK cells; rapid and enhanced
responsiveness of these cells to subsequent cytokine stimulation;
FIGURE 7. Impact of HCMV infection status on postvaccination NK cell responses. NK cell IFN-g, CD107a, and CD25 responses are shown for 33
HCMV IgG-seronegative (open symbol) and 19 HCMV IgG-seropositive individuals (closed symbol) after stimulation with H1N1 virus alone (A–C), H1N1
in the presence of LCC (D–F), or HCC (G–I) before (0) or 2, 4, or 12 wk after vaccination. Bars represent mean values. Comparisons between HCMV2 and
HCMV+ individuals were made using Mann–Whitney U tests. *p , 0.05, **p , 0.01, ***p , 0.001.
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and, in the absence of further boosting or infection, a resting or
reversion phase (Supplemental Fig. 4).
Our in vitro model of long-term NK cell preactivation by H1N1
influenza demonstrates a role for IFN-abR2 in virus-induced
preactivation. This is consistent with studies in IFN-aR2/2 mice
that point to a role for IFN-a in murine CMV- (MCMV)–driven
NK cell expansion and memory cell formation, in this case by
prevention of fratricidal killing (36), and for type I IFNs (but not
IL-12 and IL-18) in induction of NK cell IFN-g and degranulation
in a murine model of influenza virus infection (37). A role for
IFN-a in preactivation of human NK cells by influenza virus is
supported by finding biologically relevant concentrations of IFN-a
in H1N1-stimulated PBMC cultures and is consistent with reports
of raised IFN-a concentrations in human plasma up to 7 d after
influenza vaccination (22). The effect of IFN-abR2 blockade was,
however, partial, raising the possibility that additional myeloid
lineage-derived cytokines contribute to influenza virus–induced
memory-like NK cells. Indeed, consistent with previous studies,
we observed some contribution of IL-12 (and IL-18) to IFN-g
production during the prestimulation phase in vitro (38). Addi-
tionally, although our in vitro studies employed inactivated vac-
cine Ag, a role for NK cell receptor–ligand interactions or
membrane-bound cytokines, as shown in other systems, has not
been excluded (38, 39). Further studies combining neutralizing/
blocking reagents will clarify whether synergies between influ-
enza induced cytokines are required for memory-like NK cell
generation.
Preactivation and memory-like NK cell generation by H1N1
influenza in vitro also demonstrates a marked acceleration of the
NK cell IFN-g response, with IFN-g+ cells detected as early as 6 h
after restimulation, rather than the 16–18-h response typically
observed for primary in vitro stimulation. This suggests that pre-
activated NK cells may be able to respond more rapidly in vivo
during infection. Similarly accelerated responses are observed in
NK cells preactivated with high concentrations of cytokine (8).
This accelerated effector response may, however, be independent
of the IL-2/CD25-driven maintenance of cytokine-responsive
CD572 NK cells that we also observed: CD25 upregulation
occurred significantly later (18 h) than the IFN-g response and
would also require IL-2 release from Ag-specific T cells. Cytokine-
induced preactivation of NK cells may therefore comprise two
distinct phases: an initial phase in which IL-12/IL-18–induced
demethylation of the IFNG locus enhances and accelerates IFN-g
production (27) and a subsequent phase in which IFN-a–induced
upregulation of CD25 facilitates IL-2–dependent proliferation of
CD572 NK cell subsets.
Experiments in which we depleted IgG from NK cell cultures
also revealed a potential contribution of Ab–Ag immune com-
plexes to CD25 upregulation, indicating that FcR-mediated signals
transduced by influenza-specific Abs and Ag may synergize with
innate cytokines to enhance NK cell responses. Notably, however,
there was sufficient influenza-specific IgG present in plasma of
unvaccinated subjects at baseline to support these responses, in-
dicating that, at least in United Kingdom adults, natural exposure
to influenza induces sufficient Ab to mediate Ab-dependent cy-
totoxic responses and that this response is not noticeably enhanced
by vaccination. It remains to be seen whether mucosal vaccine-
induced IgA can augment responses of Fca+ NK cells to influenza
infection (30, 40).
Our studies reveal a redistribution of NK cell subsets according
to their differentiation stage after both H1N1 and cytokine pre-
activation of NK cells in vitro and in NK cells sampled ex vivo
before and after vaccination. In vitro priming with H1N1 clearly
favors enrichment of cells lacking the late differentiation marker
CD57. One caveat of our in vitro model is the potential for
preferential activation and maintenance of CD56brightCD572
CD94+ cells, with higher sensitivity for cytokines, within
influenza-stimulated cultures. However, we observed no overall
change in the frequency and CD56bright NK cells ex vivo after
influenza vaccination, whereas significant redistribution occurred
within CD56dim NK cells. This was particularly evident in
HCMV+ individuals, with the effect that 2 wk after vaccination,
FIGURE 8. Responses of CD57-defined NK cell subsets and impact of HCMVexposure. (A) Gating strategy for CD57-defined NK cell subsets. PBMCs
were restimulated with H1N1 and IFN-g (B and E), CD107a (C and F), and CD25 (D and G) responses were analyzed for each CD56/CD57-defined NK cell
subset. (B–D) Responses for cells collected 2 wk after vaccination are stratified by HCMV infection status: open circles, HCMV2 (n = 33) individuals;
closed circles, HCMV+ (n = 19) individuals. Bars represent mean values. Significant values for trends across CD56dim NK cell subsets (repeated-measures
ANOVA) and comparisons between HCMV2 and HCMV+ individuals (Mann–Whitney U test) are shown. (E–G) For each subset, baseline (0) responses are
compared with postvaccination (2 wk) by Wilcoxon signed-rank test; paired data for each individual are joined by a solid line. *p , 0.05, **p , 0.01,
***p , 0.001, ****p , 0.0001.
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the ratio of CD572 to CD57+ cells in HCMV+ subjects has been
restored to levels seen in HCMV2 subjects. The increased fre-
quencies of Ki67+ and CD71+CD56dimCD572 NK cells that we
observed ex vivo after influenza vaccination are, however, con-
sistent with proliferative expansion of CD56dimCD572 cells and
reminiscent of data on yellow fever vaccination in which CD57-
defined subset redistribution correlated strongly with increased
Ki67 expression (41). These data thus confirm and extend obser-
vations made previously for cytokine preactivated NK cells (8)
and suggest that any benefits of cytokine-mediated preactivation
may be particularly apparent in HCMV+ individuals.
This study reveals important differences between NK cell re-
sponses to influenza Ags and those driven by high concentrations
of exogenous cytokines, which may underlie the differential
responsiveness in HCMV2 and HCMV+ individuals. Although
vaccine-mediated preactivation may play a role in boosting NK
cell responses to influenza virus both in HCMV2 and HCMV+
subjects, lower CD25 expression in HCMV+ individuals (partic-
ularly on late differentiated NK cells) could limit the impact of
T cell–derived IL-2 in costimulation and maintenance of memory-
like NK cells. Lower frequencies of CD25 expressing NK cells in
HCMV-infected subjects after H1N1 stimulation may be partially
FIGURE 9. Impact of influenza vaccination and HCMV infection status on ex vivo NK cell-surface phenotype. Frequencies of CD56bright and CD56dim
CD57-defined subsets (A), CD94-, NKG2A-, and NKG2C-expressing NK cells (B), and NKG2A+CD57+ or NKG2C+CD57+ NK cells (C) were measured
directly ex vivo before (0) or 2 wk after vaccination for all 52 study subjects. NK cells from HCMV2 (open circles; n = 33) and HCMV+ (closed circles; n =
19) subjects were compared for ex vivo frequencies of CD25+ cells (D), proportions of cells in each subset (E), and the ratio of CD56dimCD572 to CD56dim
CD57+ cells before (0) or 2 wk after vaccination (F) and for frequencies of NK cells in each subset expressing Ki67 (G) or Ki67 in combination with CD71
(H) 2 wk after vaccination. Bars represent mean values. Mann–Whitney U test was used for intergroup comparisons, and trend analysis was performed
using a one-way ANOVA with correction for repeated measures. ** p , 0.01, ***p , 0.001, ****p , 0.0001.
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attributed to reduced IFN-a production because median concen-
trations of IFN-a in H1N1 culture supernatants were marginally
lower among HCMV+ individuals than among HCMV2 individ-
uals (baseline: 401.0 and 194.3 pg/ml, respectively; 2 wk post-
vaccination: 214.8 and 141.7 pg/ml, respectively), but these
differences did not reach statistical significance. In contrast, cells
from HCMV+ donors responded much less well to IL-12 and IL-
18 compared HCMV2 individuals, but this defect was partially
overcome after vaccination.
The longevity of memory-like NK cells may well be linked to
the duration of the underlying stimulus, being longer lasting when
induced by a virulent, replicating virus such as hantavirus or
yellow fever virus (41, 42) than when induced by vaccination (as
in this study) or by exogenous cytokines (7, 8). The use of an
inactivated vaccine in our studies, although not completely
ruling out the possibility of the persistence of residual Ag,
supports a model in which cytokine preactivation outlasts
clearance of Ag. Our observation of similar levels of NK cell
preactivation induced by mucosal, dermal, and i.m. vaccination
supports a role for common, systemically produced factors. In-
trinsic changes affecting cytokine responsiveness, including
epigenetic changes, combined with upregulation of CD25, are
likely to be involved in the induction and maintenance of
memory-like NK cells, particularly those that are relatively
undifferentiated.
Our data, and that of others, reveal differences between the
global effects of cytokine-induction of memory-like NK cells and
more specific, receptor-mediated, ITIM-dependent generation of
memory NK cells. Ligation of murine Ly49H by MCMV m157
generates Ly49H+ NK cells with long-term enhanced respon-
siveness to MCMV. In humans, NK cells expressing NKG2C or
activating killer Ig-like receptor expand in response to HCMV-
infected fibroblasts in vitro and adaptive expansions of NKG2C+
cells (as well as NKG2C2 cells lacking the FcεRg signaling
adaptor) are evident in the blood of HCMV+ individuals (43–47).
By contrast, we found no evidence that cytokine-mediated gen-
eration of memory-like NK cells after vaccination favored par-
ticular NKG2A- or NKG2C-defined NK cell subsets.
Although the pathways involved in the generation of cytokine-
induced memory-like NK- and ITIM-generated memory NK cells
may be distinct, it is likely that cytokine-driven mechanisms can
impact the latter populations. NK cells of HCMV+ individuals may
be skewed toward CD57+ Ab-dependent effectors, but these in-
dividuals nevertheless retain the capacity to expand a population
of highly cytokine-responsive and cytokine-producing cells in
situations (such as acute infection, mimicked in this case by
vaccination) when this would be advantageous: cytokine respon-
siveness of CD57+ NK cells was enhanced after vaccination.
Furthermore, several studies indicate a role for cytokines in the
regulation of NK cells that have been expanded by interactions
with infected target cells. IL-12 in particular is essential for
induction of CD25 and for generation and maintenance of
memory-like NK cells in MCMV-infected mice (48, 49) and for
upregulation of CD25 on NKG2C+ NK cells in response to
HCMV/HLA-E (45). In addition, enhanced cytokine responsive-
ness in NKG2Cbright NK cells may be facilitated by epigenetic
reprogramming of the IFN-g locus after specific receptor–ligand
interactions (50). It is likely that different pathogens preactivate
NK cells via distinct combinations of cytokines depending upon
pathogen-specific TLR ligands stimulating particular myeloid
cell populations (5, 22). Furthermore, heterologous infections may
maintain cytokine preactivated NK cells; by contrast, MCMV-
primed NK cells show very limited responses to bystander
infections (49).
The impact of influenza vaccination on NK cell responses seems
to reflect the kinetics of memory-like NK cell generation rather
than availability of T cell help, because T cell IL-2 responses did
not differ significantly over the course of the study. Cytokine-
induced preactivation of NK cells for enhanced IFN-g produc-
tion could therefore be of significance in protection against
influenza, with the extent of memory-like NK cell generation
impacting on overall vaccine-induced protection. Further studies
will be required to establish the relationship between memory-like
NK cell generation by different vaccine formulations and subse-
quent responses to virus challenge.
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